Current
31.7×
5-Year Average
44.7×
All-Time High
1122.7×
All-Time Low
4.9×
EV/EBITDA daily chart for Eli Lilly (LLY)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical EV/EBITDA for Eli Lilly (LLY) from 2001 to 2025
| 2025 | $965.06B | $27.94B | 35.8× | -11.7× | |
| 2024 | $692.90B | $15.23B | 47.5× | -16.3× | |
| 2023 | $524.27B | $8.57B | 63.8× | +22.0× | |
| 2022 | $347.61B | $8.66B | 41.8× | +7.4× | |
| 2021 | $263.42B | $8.04B | 34.4× | +14.8× | |
| 2020 | $161.51B | $8.91B | 19.6× | -0.6× | |
| 2019 | $125.85B | $6.90B | 20.2× | -1.7× | |
| 2018 | $118.93B | $5.56B | 21.9× | -1.8× | |
| 2017 | $88.85B | $3.99B | 23.7× | +6.8× | |
| 2016 | $80.97B | $5.06B | 16.9× | -5.2× | |
| 2015 | $93.13B | $4.38B | 22.1× | +4.4× | |
| 2014 | $76.62B | $4.53B | 17.6× | +10.1× | |
| 2013 | $56.96B | $7.50B | 7.6× | -0.4× | |
| 2012 | $56.55B | $7.05B | 8.0× | +1.3× | |
| 2011 | $46.37B | $6.91B | 6.7× | +1.9× | |
| 2010 | $38.86B | $8.04B | 4.9× | -1.1× | |
| 2009 | $39.21B | $6.92B | 6.0× | -1116.7× | |
| 2008 | $44.08B | $43.30M | 1122.7× | +1112.7× | |
| 2007 | $58.20B | $5.85B | 10.0× | -1.5× | |
| 2006 | $56.51B | $4.93B | 11.4× | -2.9× | |
| 2005 | $61.45B | $4.38B | 14.4× | +0.2× | |
| 2004 | $61.37B | $4.26B | 14.2× | -4.8× | |
| 2003 | $75.89B | $4.05B | 19.0× | +0.8× | |
| 2002 | $68.26B | $3.82B | 18.2× | -1.9× | |
| 2001 | $84.56B | $4.18B | 20.1× | — |
- 202535.8×
- 202447.5×
- 202363.8×
- 202241.8×
- 202134.4×
- 202019.6×
- 201920.2×
- 201821.9×
- 201723.7×
- 201616.9×
- 201522.1×
- 201417.6×
- 20137.6×
- 20128.0×
- 20116.7×
- 20104.9×
- 20096.0×
- 20081122.7×
- 200710.0×
- 200611.4×
- 200514.4×
- 200414.2×
- 200319.0×
- 200218.2×
- 200120.1×
About EV/EBITDA at Eli Lilly (LLY)
Eli Lilly (LLY) EV/EBITDA ratio is 31.7× as of June 5, 2026. The 5-year average is 44.7×. The sector median currently stands at 15.0×. The current ratio is at the 19th percentile of its own 10-year history.
Eli Lilly (LLY) historical EV/EBITDA ratio has ranged from a low of 4.9× (2010) to a high of 1122.7× (2008) in the available daily series.
The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.
Eli Lilly EV/EBITDA by Year
Eli Lilly EV/EBITDA 2025: 35.8×
Eli Lilly (LLY) EV/EBITDA ratio in 2025 was 35.8×, contracted from 47.5× the prior year.
Eli Lilly EV/EBITDA 2024: 47.5×
Eli Lilly (LLY) EV/EBITDA ratio in 2024 was 47.5×, contracted from 63.8× the prior year.
Eli Lilly EV/EBITDA 2023: 63.8×
Eli Lilly (LLY) EV/EBITDA ratio in 2023 was 63.8×, expanded from 41.8× the prior year.
Eli Lilly EV/EBITDA 2022: 41.8×
Eli Lilly (LLY) EV/EBITDA ratio in 2022 was 41.8×, expanded from 34.4× the prior year.
Eli Lilly EV/EBITDA 2021: 34.4×
Eli Lilly (LLY) EV/EBITDA ratio in 2021 was 34.4×.
EV is calculated as Market Cap + Total Debt − Cash & Short-Term Investments (simplified). Minority interest and preferred equity are excluded due to data availability. This is consistent with the methodology used by most public financial data providers.
Sector peers by EV/EBITDA — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by EV/EBITDA — table
Healthcare peers of Eli Lilly (LLY), ranked by EV/EBITDA ratio.
| 13.9× | |
| 13.6× | |
| 13.6× | |
| 13.2× | |
| 12.9× | |
| 12.9× | |
| 12.7× | |
| 12.4× | |
| 12.0× | |
| 11.7× | |
| 11.5× | |
| 11.5× | |
| 11.2× | |
| 10.5× | |
| 10.0× | |
| 8.8× | |
| 8.5× | |
| 8.2× | |
| 7.9× | |
| 7.8× | |
| 6.8× | |
| 6.5× | |
| 5.8× | |
| 5.7× | |
| 4.5× |
- 13.6×
- 13.2×
- 12.9×
- 12.4×
- 12.0×
- 11.7×
- 11.5×
- 10.5×
- 10.0×
- 8.5×
- 8.2×
- 7.9×
- 7.8×
- 5.8×
- 4.5×
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric